Reolysin: Updated Phase II data

Oncolytics reported updated data from 25 evaluable chemotherapy-naïve patients with stage IIIB or IV metastatic or recurrent SCC of the lung in the 2-stage, open-label, U.S. Phase II REO 021 trial showing that IV Reolysin plus paclitaxel and carboplatin produced a disease control rate (DCR) of 92%, including 10 partial responses (PR) and 13 cases of stable disease (SD). Mean tumor shrinkage was 32.7%. Earlier this year, Oncolytics reported that the trial met its primary endpoint of an ORR of >=35%. Specifically, in 21 evaluable patients, Reolysin plus paclitaxel and carboplatin led to an ORR of 42.8%, including 9 PRs plus 9 cases of SD (see BioCentury, Feb. 11 & April 1). Patients received IV Reolysin on days 1-5 plus paclitaxel and carboplatin on day 1 of a 21-day cycle. Oncolytics plans to report final PFS data from the trial this year. The company said it plans to conduct additional studies in the indication, but declined to disclose details. ...